Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Coussens

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Cell Death & Disease|June 24, 2011
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistanceD Barbone, J A Ryan, N Kolhatkar, et al.
Oncogene|August 11, 2010
EMX2 is epigenetically silenced and suppresses growth in human lung cancerJ Okamoto, T Hirata, Z Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2021
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE studyM Tempero, D-Y Oh, J Tabernero, et al.
Science (New York, N.Y.)|November 4, 2017
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patientsV Gopalakrishnan, C N Spencer, L Nezi, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Cell Death & Disease|June 24, 2011
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistanceD Barbone, J A Ryan, N Kolhatkar, et al.
Oncogene|August 11, 2010
EMX2 is epigenetically silenced and suppresses growth in human lung cancerJ Okamoto, T Hirata, Z Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2021
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE studyM Tempero, D-Y Oh, J Tabernero, et al.
Science (New York, N.Y.)|November 4, 2017
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patientsV Gopalakrishnan, C N Spencer, L Nezi, et al.
Pageof 2